Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2021

01-02-2021 | COVID-19 | Letter to the Editor

Testosterone in COVID-19: Friend or Foe?

Authors: Peter J. Niemann, Heidi V. Goldstein

Published in: Endocrine | Issue 2/2021

Login to get access

Excerpt

Coronavirus disease 2019 (COVID-19) as an ongoing disruptive pandemic poses significant challenges for the clinician. The pathogen responsible for COVID-19 is severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). Although it is primarily a viral infection that affects the lower respiratory tract and lungs, it can target essentially all major organ systems. Endocrinological considerations surrounding testosterone seem particularly in need of discussion and to date present a management challenge, partly due to lack of high-quality evidence and resulting controversial interpretations. …
Literature
1.
2.
S. Salciccia, F. Del Giudice, M.L. Eisenberg, C.M. Mastroianni, E. De Berardinis, G.P. Ricciuti, M. Maggi, A. Sciarra, Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone. Ther. Adv. Endocrinol. Metab. (2020). https://​doi.​org/​10.​1177/​2042018820969019​
3.
G. Rastrelli, V. Di Stasi, F. Inglese, M. Beccaria, M. Garuti, D. Di Costanzo, F. Spreafico, G.F. Greco, G. Cervi, A. Pecoriello, A. Magini, T. Todisco, S. Cipriani, E. Maseroli, G. Corona, A. Salonia, A. Lenzi, M. Maggi, G. De Donno, L. Vignozzi, Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology (2020). https://​doi.​org/​10.​1111/​andr.​12821
Metadata
Title
Testosterone in COVID-19: Friend or Foe?
Authors
Peter J. Niemann
Heidi V. Goldstein
Publication date
01-02-2021
Publisher
Springer US
Published in
Endocrine / Issue 2/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02623-2

Other articles of this Issue 2/2021

Endocrine 2/2021 Go to the issue

Review

Consequences of atmospheric contamination by radioiodine: the Chernobyl and Fukushima accidents

Original Article

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

Endocrine Genetics/Epigenetics

Compound heterozygous GLI3 variants in siblings with thyroid hemiagenesis

Original Article

Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer

Original Article

Clinical characteristics and incidence of glucose metabolism disorders during the follow-up of surgically treated insulinomas

Original Article

The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits